Pioneering the early path to translation: one scientist-inventor’s journey
Presented by Dr James (Jim) Aylward, Oncolin
Dr Jim Aylward holds a PhD in Biochemistry from Monash University. He was a CSIRO Principal Scientist prior to leaving the Organisation and founding his own biotech – drug – development company, Peplin, in 1998. On the strength of his own patents on the anti-cancer principles from the plant Euphorbia peplus, and as Executive Director, he obtained seed finance, grew the company, and guided the R&D program through to public listing on the ASX in September 2000. In 2004, Peplin filed INDs with the FDA for the clinical development of PEP-005 (later ingenol mebutate) for the treatment of actinic keratosis. Leo Pharma (A/S) acquired Peplin in 2010, and in March 2011, successfully filed an NDA with the FDA for ingenol mebutate, which is marketed internationally under the tradename “Picato”.
Dr Aylward has continued to help small tech startups in a mentoring capacity through iLab in Toowong (2004-2010), and the Mentoring for Growth program (Queensland Government). He was an assessor for the Australian Technology Showcase (2009-2012). Dr Aylward was joint winner of the 2012 LSQ Excellence award, in recognition of his contribution to the life sciences industry.
Dr Aylward will recount the formative years of Peplin, with its attendant trials and tribulations.
Date: Thursday 13 June 2013
Venue: Goddard Building 08, Lecture Room 139, University of Queensland (St Lucia Campus)
For more information about the seminars please contact Petrina Gilmore, phone 07 3346 3899.